Quick Answer
Atara Biotherapeutics, Inc. reported Diluted EPS of $2.57 per share for fiscal year 2025.
Atara Biotherapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $2.57 | +122.5% |
| 2024 | -$11.41 | +82.5% |
| 2023 | -$65.19 | -2810.3% |
| 2022 | -$2.24 | +38.3% |
| 2021 | -$3.63 | +12.5% |
| 2020 | -$4.15 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.32 | +89.1% | -268.4% |
| June 30, 2025 | $0.19 | +106.1% | -94.6% |
| March 31, 2025 | $3.50 | +161.9% | +219.5% |
| September 30, 2024 | -$2.93 | +82.1% | +5.5% |
| June 30, 2024 | -$3.10 | +81.7% | +45.1% |
| March 31, 2024 | -$5.65 | -684.7% | +65.5% |
| September 30, 2023 | -$16.40 | -1900.0% | +3.0% |
| June 30, 2023 | -$16.91 | -9494.4% | -2248.6% |
- Atara Biotherapeutics, Inc. showed an increase of +122.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Atara Biotherapeutics, Inc.’s diluted eps has grown by 161.9% (from $4.15 per share (loss) to $2.57 per share).
- The most recent figure is from Atara Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: